

## Special Issue

# Molecular Epidemiology and Antimicrobial Resistance Trends in Gram-Negative Bacteria and *Mycobacterium tuberculosis*

### Message from the Guest Editors

This Special Issue seeks to explore current advancements in the molecular epidemiology of antimicrobial resistance (AMR), with a particular emphasis on Gram-negative bacteria, *Mycobacterium tuberculosis*, and nontuberculous mycobacteria (NTM). The focus will be on understanding the mechanisms driving resistance and virulence, the transmission dynamics within different environments, and the clinical outcomes associated with these high-priority pathogens. We encourage researchers to contribute original research, comprehensive reviews, and case studies that examine the molecular mechanisms of resistance, innovative therapeutic approaches, breakthroughs in diagnostic methods, epidemiological patterns, and the broader clinical impact of AMR in these pathogens. Short and case reports are also welcome based on the relevance of data.

---

### Guest Editors

Dr. Karla Valéria Batista Lima  
Dr. Yan Corrêa Rodrigues  
Dr. Danielle Murici Brasiliense

---

### Deadline for manuscript submissions

closed (31 March 2025)



## Antibiotics

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.6  
CiteScore 8.7  
Indexed in PubMed



[mdpi.com/si/217357](https://mdpi.com/si/217357)

*Antibiotics*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[antibiotics@mdpi.com](mailto:antibiotics@mdpi.com)

[mdpi.com/journal/  
antibiotics](https://mdpi.com/journal/antibiotics)





# Antibiotics

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.6  
CiteScore 8.7  
Indexed in PubMed



[mdpi.com/journal/  
antibiotics](https://mdpi.com/journal/antibiotics)



## About the Journal

### Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

---

### Editor-in-Chief

Prof. Dr. Nicholas Dixon  
School of Chemistry and Molecular Bioscience, University of  
Wollongong, Wollongong, NSW 2522, Australia

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)